WILMINGTON, N.C. & MARIETTA, Ga. -- (BUSINESS WIRE) -- Osmotica Pharmaceutical Corp. today announced the appointment of Steve Banet as Vice President, Head of Commercial Development. He will be responsible for development of Osmotica’s sales and marketing presence, building Osmotica’s commercial infrastructure and leading the business development activities. “We are pleased to welcome someone with Steve’s background and experience to the Osmotica senior leadership team. As we become a fully integrated company, we will leverage Steve’s expertise to build our commercial infrastructure,” stated Praveen Tyle, PhD, President and CEO for Osmotica Pharmaceutical.
Mr. Banet is a 30 year veteran of the pharmaceutical industry with extensive experience in commercial operations, trade affairs, marketing and new business development. Prior to his appointment at Osmotica, he was Vice President, Head of U.S. Business Development for UCB Inc. During his 12 year tenure at UCB, Mr. Banet held positions of increasing responsibility including Vice President of Commercial Operations, Sr. Director Trade Relations and Director of Marketing Research. Prior to joining UCB, Mr. Banet held a variety of positions in product management, business information and business operations at Mallinckrodt, Inc., Schering-Plough, Solvay Pharmaceuticals, and Countrymark Cooperative, a supply and marketing cooperative.
Mr. Banet holds a bachelor’s of Science degree from Purdue University; a master’s of Science degree from the University of Tennessee in Knoxville, TN; and a master’s in Business Administration in Marketing from Indiana Wesleyan University.
About Osmotica Pharmaceutical
Osmotica Pharmaceutical is a global specialty pharmaceutical company with a proven history of developing commercially successful pharmaceutical products. The company uses its proprietary osmotic technology platform and with strategic partners develops and commercializes high quality pharmaceutical products. In addition to the products currently on the market, the company’s pipeline includes numerous ANDA programs and several innovative neurology-based NDA programs.
Osmotica Pharmaceutical and its related companies form an international group of companies with principal operations located in the United States, Argentina and Hungary.
For more information on the Company, please visit Osmotica’s website at www.osmotica.com. This press release is directed to residents of the United States.